Biostage, Inc., a biotechnology company, engages in developing bioengineered organ implants based on its Cellframe technology. The company's Cellframe technology combines a proprietary biocompatible scaffold with a patient's own stem cells to create Cellspan organ implants. It is developing bioengineered organ implants, which addresses the damage of the esophagus, bronchus, and trachea due to cancer, infection, trauma, or congenital abnormalities. The company was formerly known as Harvard Apparatus Regenerative Technology, Inc. and changed its name to Biostage, Inc. in March 2016. Biostage, Inc. was founded in 2007 and is headquartered in Holliston, Massachusetts.
Industry, Sector and Symbol
Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
Phone774-233-7300
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees15
Next Earnings Date3/26/2020 (Estimated)
OptionableNot Optionable
Biostage (OTCMKTS:BSTG) Frequently Asked Questions
What is Biostage's stock symbol?
Biostage trades on the OTCMKTS under the ticker symbol "BSTG."
How were Biostage's earnings last quarter?
Biostage Inc (OTCMKTS:BSTG) announced its earnings results on Tuesday, November, 12th. The company reported ($0.33) earnings per share (EPS) for the quarter. View Biostage's Earnings History.
When is Biostage's next earnings date?
Has Biostage been receiving favorable news coverage?
Headlines about BSTG stock have trended somewhat positive this week, InfoTrie reports. The research firm identifies positive and negative media coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Biostage earned a news sentiment score of 1.3 on InfoTrie's scale. They also assigned news headlines about the company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an effect on the company's share price in the immediate future. View News Stories for Biostage.
Who are some of Biostage's key competitors?
Some companies that are related to Biostage include AIT Therapeutics (AITB), Sensus Healthcare (SRTS), Nephros (NEPHD), Pro-Dex (PDEX), STRATA Skin Sciences (SSKN), Motus GI (MOTS), Apollo Endosurgery (APEN), PAVmed (PAVM), T2 Biosystems (TTOO), SANUWAVE Health (SNWV), Arch Therapeutics (ARTH), Invo Bioscience (IVOB), Endologix (ELGX), Neovasc (NVCN) and Interpace Diagnostics Group (IDXG).
What other stocks do shareholders of Biostage own?
Who are Biostage's key executives?
Biostage's management team includes the folowing people:
- Mr. James J. McGorry, CEO & Director (Age 63)
- Mr. Thomas W. McNaughton, CFO & Sec. (Age 59)
- Yu Hong, Pres (Age 46)
- Ms. Ginger A. Abraham-Freel, Director of Quality & Operations
- Dr. William L. Fodor Ph.D., Chief Scientific Officer (Age 60)
How do I buy shares of Biostage?
Shares of BSTG can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Biostage's stock price today?
One share of BSTG stock can currently be purchased for approximately $2.21.
How big of a company is Biostage?
What is Biostage's official website?
How can I contact Biostage?
Biostage's mailing address is 84 October Hill Road Suite 11, Holliston MA, 01746. The company can be reached via phone at 774-233-7300 or via email at [email protected]
MarketBeat Community Rating for Biostage (OTCMKTS BSTG)
MarketBeat's community ratings are surveys of what our community members think about Biostage and other stocks. Vote "Outperform" if you believe BSTG will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BSTG will underperform the S&P 500 over the long term. You may vote once every thirty days.
